Acute Cholecystitis: Tokyo Guidelines TG18 Diagnosis, Severity Grading, and Management
Executive Summary
Acute cholecystitis is gallbladder inflammation, most often caused by cystic duct obstruction by gallstones (90-95%). The Tokyo Guidelines (TG18) provide the international standard for diagnosis (combining local signs, systemic inflammation, and imaging) and severity grading (Grade I mild, Grade II moderate, Grade III severe with organ dysfunction). Definitive treatment is laparoscopic cholecystectomy, performed early (within 72 hours of symptom onset, ideally during the index admission) for Grade I and selected Grade II disease. Percutaneous transhepatic gallbladder drainage (PT-GBD) is the rescue option for high-risk patients with Grade III cholecystitis or those who fail to respond to antibiotics.
Empiric antibiotic coverage targets enteric Gram-negative rods (E. coli, Klebsiella, Enterobacter) and anaerobes; piperacillin-tazobactam or a third-generation cephalosporin plus metronidazole is appropriate first-line. Acalculous cholecystitis (5-10%) occurs in critically ill patients (sepsis, trauma, burns, prolonged TPN) and carries higher mortality (30-50%) than calculous disease (~1-3%). Recognition of complications (gangrenous cholecystitis 2-30%, emphysematous cholecystitis in diabetics, gallbladder perforation 10%, Mirizzi syndrome) requires urgent surgical or percutaneous intervention.
Table of Contents
- Pathophysiology and Clinical Presentation
- Calculous vs acalculous mechanisms
- Symptom evolution & physical signs
- TG18 Diagnostic Criteria and Severity Grading
- A/B/C diagnostic triad
- Grade I/II/III stratification
- Imaging and Differential Diagnosis
- RUQ ultrasound first-line
- HIDA for equivocal cases
- Antibiotic Therapy and Initial Resuscitation
- Surgical Timing and Percutaneous Drainage
- Complications and Special Populations
S1. Pathophysiology and Clinical Presentation
Calculous cholecystitis (90-95%)
The disease cascade begins with persistent obstruction of the cystic duct by a gallstone impacted in the neck of the gallbladder or in Hartmann’s pouch. Continued mucin and water secretion against an obstructed outflow distends the gallbladder wall, mechanically compromising venous and lymphatic drainage. Within hours, mucosal ischemia liberates phospholipase A2 from gallbladder mucosa, hydrolyzing biliary lecithin to lysolecithin, which is directly cytotoxic and amplifies chemical inflammation. Prostaglandins (especially PGE2 and PGI2) are then upregulated and drive the early phase of pain and edema, which is why intravenous NSAIDs (e.g., diclofenac, ketorolac) blunt biliary colic. Bacterial superinfection follows mechanical and chemical injury rather than initiating it: bile cultures are positive in 22-46% of patients in the first 48 hours but exceed 80% in gangrenous or perforated disease.
Acalculous cholecystitis (5-10%)
Acalculous disease arises from gallbladder wall ischemia, bile stasis, and reperfusion injury rather than mechanical obstruction. The classic setting is a critically ill ICU patient with multiple risk factors clustered together: sepsis with vasopressor support, trauma, burns, prolonged mechanical ventilation, total parenteral nutrition, postoperative status (especially cardiothoracic and aortic surgery), AIDS-related opportunistic infection (CMV, cryptosporidium), and diabetes mellitus. Mortality reaches 30-50% because the diagnosis is often delayed by sedation, mechanical ventilation, and confounding sources of fever and abdominal tenderness; aggressive imaging surveillance with bedside ultrasound is essential when ICU patients develop unexplained fever, leukocytosis, or right upper quadrant findings.
Clinical presentation
Patients typically describe a postprandial onset of right upper quadrant or epigastric pain that radiates to the right scapula or shoulder (referred pain via the phrenic nerve) and persists beyond 6 hours, distinguishing acute cholecystitis from uncomplicated biliary colic, which usually resolves within 4-6 hours. Nausea, vomiting, anorexia, and low-grade fever (38-38.5°C) are common; high-grade fever (>39°C), rigors, or hypotension should raise suspicion for ascending cholangitis, gangrenous cholecystitis, or perforation. The hallmark physical finding is a positive Murphy sign: deep palpation in the right subcostal region during inspiration causes the patient to abruptly halt inspiration because the inflamed gallbladder descends to contact the examiner’s fingers. Sonographic Murphy sign (focal tenderness directly over the gallbladder during real-time ultrasound) has higher diagnostic accuracy (sensitivity ~85%, specificity ~85%) than the bedside maneuver alone, particularly in obese patients.
Key teaching point
Pain that lasts >6 hours, fever, leukocytosis, and a positive Murphy sign together carry a positive predictive value of ~70% for acute cholecystitis even before imaging. Treat empirically while awaiting confirmatory studies in the right clinical context.
S2. TG18 Diagnostic Criteria and Severity Grading
TG18 diagnostic criteria
The Tokyo Guidelines define a tripartite diagnostic framework. Suspected diagnosis requires one item from category A and one from category B; definite diagnosis requires one item each from A, B, and C.
| Category | Criteria | Notes |
|---|---|---|
| A. Local signs of inflammation | (1) Murphy sign (2) Right upper quadrant mass / pain / tenderness | At least one required |
| B. Systemic signs of inflammation | (1) Fever >38°C (2) Elevated CRP (≥3 mg/dL) (3) Elevated WBC count (>10,000/mm³) | At least one required |
| C. Imaging findings | Characteristic findings of acute cholecystitis on US, CT, or MRI | Required for definite diagnosis |
TG18 severity grading
Severity grading drives treatment decisions, including the urgency of source control, the need for ICU admission, and patient suitability for early laparoscopic cholecystectomy versus percutaneous drainage.
| Grade | Definition | Mortality / Implication |
|---|---|---|
| Grade I (Mild) | Acute cholecystitis without organ dysfunction; mild local inflammation; safe candidate for early laparoscopic cholecystectomy | ~1% mortality; index-admission cholecystectomy preferred |
| Grade II (Moderate) | Any of: WBC >18,000/mm³; palpable tender mass in RUQ; symptoms >72 h; marked local inflammation (gangrenous or emphysematous cholecystitis, pericholecystic abscess, hepatic abscess, biliary peritonitis) | ~2-5% mortality; early lap chole if expertise available, otherwise PT-GBD bridge |
| Grade III (Severe) | Acute cholecystitis with dysfunction in any organ system: cardiovascular (hypotension requiring dopamine ≥5 mcg/kg/min or any norepinephrine), neurological (decreased consciousness), respiratory (PaO&sub2;/FiO&sub2; <300), renal (oliguria, Cr >2.0 mg/dL), hepatic (PT-INR >1.5), or hematological (platelets <100,000/mm³) | ~10-30% mortality; urgent gallbladder drainage and ICU resuscitation; delayed cholecystectomy after stabilization |
S3. Imaging and Differential Diagnosis
Right upper quadrant ultrasound (first-line)
Transabdominal ultrasound is the initial imaging modality for suspected acute cholecystitis with pooled sensitivity 81% and specificity 83%. It is rapid, inexpensive, requires no contrast, and can be performed at the bedside in unstable patients. Diagnostic findings include gallstones (cholelithiasis), gallbladder wall thickening >4-5 mm (in the absence of ascites, hepatitis, or hypoalbuminemia which thicken the wall non-specifically), pericholecystic fluid, gallbladder distension >5 cm transverse diameter, and the sonographic Murphy sign. The sonographic Murphy sign is the single most specific finding in the acute setting and outperforms the bedside Murphy sign in obese patients.
CT abdomen with intravenous contrast
CT is the preferred modality when ultrasound is non-diagnostic, when complications are suspected (perforation, abscess, gas in the gallbladder wall suggesting emphysematous cholecystitis), or when the differential includes other intra-abdominal pathology. CT has higher sensitivity for detecting gangrenous cholecystitis (gas in the gallbladder wall, intraluminal membranes representing sloughed mucosa, irregular wall enhancement, pericholecystic abscess) and is essential for surgical planning in complicated disease. CT does not reliably detect non-calcified cholesterol stones, so a normal CT does not exclude calculous cholecystitis if ultrasound shows stones.
Cholescintigraphy (HIDA scan)
HIDA (hepatobiliary iminodiacetic acid) scintigraphy is reserved for cases where ultrasound and CT are equivocal but clinical suspicion remains high, particularly when acalculous cholecystitis is suspected in critically ill patients. Failure of the gallbladder to fill within 1 hour of radiotracer injection (or within 4 hours with morphine augmentation) constitutes a positive scan. HIDA has the highest sensitivity (~96%) and specificity (~90%) of any imaging modality for acute cholecystitis but is rarely needed when ultrasound is diagnostic. Limitations include long study time, false-positives in prolonged fasting or TPN-dependent patients (chronic gallbladder distension prevents filling), and limited availability outside business hours.
Differential diagnosis
| Condition | Distinguishing features |
|---|---|
| Biliary colic (uncomplicated) | Pain <4-6 h, no fever, no leukocytosis, normal LFTs, no Murphy sign |
| Choledocholithiasis | Jaundice, elevated bilirubin/ALP/GGT, dilated CBD >6 mm on US, may coexist with cholecystitis |
| Ascending cholangitis | Charcot triad (fever, jaundice, RUQ pain) or Reynolds pentad (+hypotension, mental status change), bacteremia, biliary obstruction |
| Acute pancreatitis | Lipase >3× ULN, epigastric pain radiating to back, often shares gallstone etiology |
| Peptic ulcer disease / perforated ulcer | Free air on upright film, sudden severe pain, tympanic abdomen |
| Right lower lobe pneumonia | Pleuritic component, cough, hypoxemia, infiltrate on chest imaging |
| Hepatic abscess | Hepatomegaly, hypodense lesion on CT, often Klebsiella in diabetic patients |
| Acute hepatitis | AST/ALT >500 U/L, viral serologies, normal gallbladder on imaging |
S4. Antibiotic Therapy and Initial Resuscitation
Empiric antibiotic regimens
Antibiotics should be initiated within 1 hour of diagnosis after appropriate cultures (blood cultures ×2 in all hospitalized patients; intraoperative or PT-GBD bile cultures when source control is performed). Empiric coverage targets enteric Gram-negative bacilli (E. coli ~40%, Klebsiella ~15%, Enterobacter ~10%, Enterococcus 10-15%) and anaerobes (Bacteroides, Clostridium, especially in elderly, diabetic, or post-biliary-instrumentation patients).
| Severity | First-line regimen | Penicillin-allergic / alternative |
|---|---|---|
| Grade I (community-acquired, no risk factors) | Ceftriaxone 1-2 g IV daily + metronidazole 500 mg IV q8h | Ciprofloxacin 400 mg IV q12h + metronidazole 500 mg IV q8h |
| Grade II (moderate, healthcare-associated risk) | Piperacillin-tazobactam 4.5 g IV q8h (extended infusion over 4 h) | Meropenem 1 g IV q8h if ESBL risk or recent broad-spectrum exposure |
| Grade III (severe, septic, ICU) | Meropenem 1-2 g IV q8h ± Vancomycin 25-30 mg/kg IV loading then AUC-guided if MRSA risk or recent admission | Add empiric anti-Candida (fluconazole 800 mg IV load → 400 mg IV daily, or echinocandin if azole-resistant) for prolonged ICU stay, TPN, or recurrent biliary instrumentation |
Streamline antibiotics based on bile and blood culture susceptibility results. Total antimicrobial duration is typically 4-7 days after adequate source control (cholecystectomy or PT-GBD with clinical improvement); shorter courses (2-3 days post-source-control) are appropriate for Grade I disease per the STOP-IT trial principles applied to biliary sepsis. For patients managed without source control (e.g., poor surgical candidates declining intervention), prolonged or recurrent courses may be needed.
Supportive care
Initial management includes nothing-by-mouth status, intravenous crystalloid resuscitation (balanced solutions such as Lactated Ringer or Plasma-Lyte preferred over normal saline to avoid hyperchloremic acidosis), correction of electrolyte derangements, and analgesia. Opioid choice is debated: morphine theoretically increases sphincter of Oddi tone and may worsen biliary pain, while meperidine has been historically preferred but is limited by its short half-life and neurotoxic metabolite (normeperidine accumulation in renal failure causes seizures). Current practice favors hydromorphone (0.5-1 mg IV q3-4h) or fentanyl (25-50 mcg IV q1-2h) titrated to comfort. Antiemetics (ondansetron 4 mg IV q6h) are routinely added.
Avoid: prolonged NPO without nutrition planning
Gallbladder stasis from prolonged fasting paradoxically worsens biliary inflammation. If definitive cholecystectomy is delayed beyond 5-7 days, initiate enteral or parenteral nutrition early to maintain gallbladder contractility (in non-obstructed cases) and to support host immunity.
S5. Surgical Timing and Percutaneous Drainage
Early laparoscopic cholecystectomy
Early laparoscopic cholecystectomy, defined as surgery during the index hospitalization within 72 hours (and ideally within 24 hours) of symptom onset, is the gold-standard treatment for Grade I and selected Grade II acute cholecystitis. The ACDC trial (Ann Surg 2013) and multiple subsequent meta-analyses confirm that early cholecystectomy compared with delayed cholecystectomy (after a 6-week interval of antibiotic treatment) reduces total hospital length of stay (mean reduction 4-7 days), reduces conversion to open cholecystectomy (similar rates 5-10% in both arms), reduces the risk of disease recurrence during the waiting interval (15-25% recurrence with delayed strategy), and does not increase complications including bile duct injury (~0.3-0.5% in expert hands).
The 72-hour window represents the period before dense inflammatory adhesions in Calot triangle obscure the critical view of safety, the cornerstone of safe cholecystectomy that requires skeletonization of the cystic duct and cystic artery with no other tubular structures entering the gallbladder. Beyond 72 hours and especially after 7-10 days, dissection becomes increasingly hazardous; in this scenario, subtotal cholecystectomy (fenestrating or reconstituting variants) preserves the posterior wall of the gallbladder against the liver bed and avoids common bile duct injury when the anatomy is obscured.
Percutaneous transhepatic gallbladder drainage (PT-GBD)
PT-GBD is image-guided placement of an 8-10 French pigtail catheter into the gallbladder, traditionally via a transhepatic route (through hepatic segments IV or V) which allows the liver parenchyma to tamponade bleeding and to seal the catheter tract. Indications include Grade III cholecystitis (organ failure precludes general anesthesia for emergency cholecystectomy), Grade II cholecystitis when expert laparoscopic surgery is unavailable or the patient fails to improve within 24-48 hours of antibiotic therapy, and Grade I-II disease in patients with prohibitive surgical risk (severe COPD, advanced cardiac failure, end-stage liver disease with portal hypertension). The CHOCOLATE trial (BMJ 2018) demonstrated that in high-risk patients (APACHE II 7-14), early laparoscopic cholecystectomy still outperforms PT-GBD when the patient can tolerate surgery (lower 1-year complications, lower mortality, fewer reinterventions); PT-GBD should be reserved for patients truly unfit for surgery.
After PT-GBD, the catheter is left in place 4-6 weeks to mature the tract, then a cholangiogram is performed before removal to confirm cystic duct patency. Approximately 40-60% of patients managed with PT-GBD will eventually undergo interval cholecystectomy once recovered; the remaining cohort may be managed expectantly, as symptom recurrence after definitive PT-GBD with patent cystic duct is approximately 20-30% over 5 years.
Endoscopic gallbladder drainage (emerging)
Endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) using lumen-apposing metal stents (LAMS) is an emerging alternative for inoperable patients, particularly those with cirrhosis or coagulopathy where transhepatic access is hazardous. Single-center series report technical success ~95% and clinical success ~90% with lower rates of recurrent cholecystitis than indwelling pigtail drains. Endoscopic transpapillary gallbladder drainage (ETGBD) via ERCP is another option but has lower technical success when the cystic duct is occluded by stone.
When to refer urgently
Transfer to a hepatobiliary surgical center within 6-12 hours for: gallbladder perforation with biliary peritonitis, gangrenous cholecystitis on imaging, emphysematous cholecystitis (gas in the gallbladder wall), Mirizzi syndrome with obstructive jaundice, suspected gallbladder cancer (mass on imaging, porcelain gallbladder, polyp >1 cm), or failure to improve within 24-48 hours of appropriate antibiotic therapy.
Practice Insights: Acute Cholecystitis — Early Laparoscopic Cholecystectomy and the EUS-GBD Emerging Bridge
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Delaying cholecystectomy until the cholecystitis has cooled off is the older reflex, and the Tokyo Guidelines replaced it with something checkable — (1) TG18 severity grading drives the early vs delayed surgical decision systematically — not gestalt; (2) early laparoscopic cholecystectomy within 7 days outperforms delayed cholecystectomy for most Grade I-II patients with reasonable surgical risk; (3) endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) has emerged as a viable alternative to percutaneous transhepatic gallbladder drainage (PTGBD) for poor surgical candidates. The “antibiotics + delayed cholecystectomy at 6 weeks” approach has been retired for most patients.
TG18 diagnostic criteria (A + B + C) + severity grading at admission
Tokyo Guidelines TG18 systematized acute cholecystitis diagnosis: A (local signs — Murphy’s, RUQ mass/pain), B (systemic inflammation — fever, WBC, CRP), C (imaging confirmation). All three required for definite diagnosis. Severity grading drives the management pathway: Grade I (mild, no organ dysfunction); Grade II (moderate, WBC > 18k, palpable mass, duration > 72h, marked local inflammation); Grade III (severe, organ dysfunction in any of CV/neuro/resp/renal/hepatic/hematologic systems). Experienced clinicians grade severity at admission and re-assess at 24-48 hours.
Early laparoscopic cholecystectomy within 7 days for Grade I-II
Tokyo 2018 and multiple subsequent meta-analyses confirmed early laparoscopic cholecystectomy (within 7 days of symptom onset) outperforms delayed cholecystectomy at 6 weeks for Grade I-II patients with reasonable surgical risk — fewer total hospital days, lower readmission, equivalent complication rates. Seasoned clinicians refer for laparoscopic cholecystectomy on hospital day 1-2 for any Grade I-II patient without prohibitive comorbidity. The “stabilize on antibiotics, come back in 6 weeks” approach left many patients with prolonged morbidity and recurrence — they have largely abandoned it.
PTGBD or EUS-GBD for poor surgical candidates
For Grade III cholecystitis with organ dysfunction or for poor surgical candidates (severe COPD, advanced cardiac disease, child-pugh C cirrhosis), experienced practitioners default to percutaneous transhepatic gallbladder drainage (PTGBD) under US guidance as the temporizing bridge. PTGBD achieves source control within hours, allowing time for organ support and recovery. EUS-guided gallbladder drainage (EUS-GBD with lumen-apposing metal stent like AXIOS) is emerging as an alternative to PTGBD — comparable efficacy, no external drain, lower rate of catheter dislodgement. For elective conversion to cholecystectomy, EUS-GBD with a stent in place can be removed at the time of surgery.
Subtotal cholecystectomy is acceptable for difficult dissection
For severely inflamed gallbladders with anatomy obscured by inflammation or chronic scarring (where attempting complete cholecystectomy risks bile duct injury), subtotal cholecystectomy (fenestrating type or reconstituting type per Strasberg) is the safe alternative. Experienced clinicians have abandoned the dogma of “complete cholecystectomy at all costs” — subtotal cholecystectomy with appropriate technique has comparable outcomes and dramatically lower bile duct injury rates in difficult cases. The surgical team should be empowered to convert intraoperatively without it being seen as failure.
Anonymized Case: Grade II Cholecystitis with Difficult Anatomy → Subtotal Cholecystectomy
A man in his late sixties presented with 3 days of progressive RUQ pain, fever 38.5°C, and nausea. Exam: Murphy’s sign positive, RUQ tenderness, no peritonitis. Labs: WBC 16,200, CRP 145, ALT 85, ALP 145, bilirubin 1.4 (mild cholestatic pattern). Ultrasound: gallbladder wall thickness 5.2 mm, pericholecystic fluid, multiple gallstones, no CBD dilation. TG18 diagnostic criteria met (A+B+C). Severity grading: Grade II (WBC at borderline 16-18k, duration > 72h, marked local inflammation). The treating clinicians started piperacillin-tazobactam 4.5 g IV q8h, IV fluids, NPO, hepatobiliary surgical consultation. Laparoscopic cholecystectomy was scheduled for hospital day 2. Operative findings: severely inflamed gallbladder with fused triangle of Calot anatomy — the cystic duct and common bile duct could not be safely identified. The surgical team converted to subtotal cholecystectomy using the fenestrating technique (Strasberg) — opening the gallbladder, removing all stones, leaving a small remnant of gallbladder wall on the cystic duct stump rather than risking bile duct injury. Recovered uneventfully; discharged on hospital day 4 with oral amoxicillin-clavulanate for 7 more days. Two-year follow-up: no recurrent biliary issues, no postoperative bile leak.
Four Protocol Deviations Seasoned Clinicians Now Default To
- TG18 diagnostic criteria (A + B + C) + severity grading (I/II/III) at admission for every suspected acute cholecystitis. A = local signs (Murphy’s), B = systemic inflammation, C = imaging. Severity drives the management pathway. Re-assess severity at 24-48 hours.
- Early laparoscopic cholecystectomy within 7 days of symptom onset for Grade I-II patients with reasonable surgical risk. Outperforms delayed cholecystectomy at 6 weeks. Schedule for hospital day 1-2 with hepatobiliary surgical consultation on admission.
- PTGBD or EUS-GBD for Grade III + organ dysfunction or poor surgical candidates. PTGBD = US-guided percutaneous drain (temporizing, allows interval cholecystectomy). EUS-GBD with lumen-apposing metal stent (AXIOS) emerging alternative — no external drain, comparable efficacy. Convert to cholecystectomy when surgically feasible.
- Subtotal cholecystectomy is the safe alternative for difficult dissection — not a failure. Fenestrating or reconstituting type per Strasberg classification. Prevents bile duct injury in obscured Calot anatomy. Outcomes comparable to complete cholecystectomy in difficult cases.
S6. Complications and Special Populations
Gangrenous cholecystitis (2-30%)
Gangrenous cholecystitis represents transmural necrosis of the gallbladder wall and is more common in elderly, male, diabetic, and immunosuppressed patients. Imaging clues include heterogeneous wall enhancement, intraluminal membranes, pericholecystic fluid, and absent or focal Murphy sign (necrotic gallbladder loses sensitivity). Mortality is 15-25% if not promptly recognized. Treatment is urgent cholecystectomy (often requiring conversion to open or subtotal approach) with broad-spectrum antibiotics; PT-GBD is generally inadequate as drainage cannot reverse transmural necrosis.
Emphysematous cholecystitis (1-3%)
Gas-forming infection (Clostridium perfringens, E. coli, Klebsiella) of the gallbladder wall and lumen, classically occurring in elderly diabetic men. CT shows gas in the wall and lumen, sometimes extending into the biliary tree (pneumobilia). Mortality is high (15-25%). Empiric antibiotic regimen should include anaerobic coverage with metronidazole 500 mg IV q8h plus piperacillin-tazobactam or carbapenem; emergency cholecystectomy is indicated.
Gallbladder perforation (~10%)
Niemeier classification: Type I (acute free perforation into the peritoneum with biliary peritonitis), Type II (subacute perforation with pericholecystic abscess), Type III (chronic perforation with cholecystoenteric fistula and possible gallstone ileus). Type I requires emergency surgery; Type II may be managed with percutaneous abscess drainage and interval cholecystectomy; Type III may present years later with bowel obstruction at the ileocecal valve (Bouveret syndrome if at the duodenum, Rigler triad on imaging: pneumobilia, ectopic gallstone, small bowel obstruction).
Mirizzi syndrome
Extrinsic compression or fistulization of the common hepatic duct by an impacted stone in the cystic duct or Hartmann pouch, presenting as obstructive jaundice with cholecystitis. Csendes classification stratifies severity from external compression alone (Type I) to complete fistula with gallbladder destruction (Types II-IV). MRCP delineates anatomy preoperatively. Type I may permit laparoscopic cholecystectomy; Types II-IV often require open surgery with biliary reconstruction (choledochoplasty or hepaticojejunostomy).
Special populations
| Population | Key considerations |
|---|---|
| Pregnancy | Second trimester optimal for laparoscopic cholecystectomy; avoid first-trimester surgery (teratogenic risk) and third trimester (uterine size limits laparoscopic access). Conservative management with antibiotics is reasonable for mild Grade I disease, recognizing 25-50% relapse rate before delivery |
| Cirrhosis (Child-Pugh B/C) | Markedly increased perioperative mortality (5-15% in Child-Pugh B/C vs <1% in Child-Pugh A); prefer PT-GBD or EUS-GBD; avoid laparoscopic in decompensated disease with ascites or coagulopathy |
| Elderly (>75 years) | Higher rates of gangrene, perforation, and atypical presentation (absent fever, minimal leukocytosis); lower threshold for CT imaging; consider PT-GBD if poor functional status or cardiopulmonary reserve |
| Pediatric | Often associated with hemolytic disease (sickle cell, hereditary spherocytosis) producing pigment stones, or with TPN-dependence; laparoscopic cholecystectomy is well tolerated when indicated |
| Critically ill ICU patient | Acalculous cholecystitis high suspicion if unexplained fever, leukocytosis, or RUQ tenderness; bedside ultrasound or HIDA; PT-GBD often preferred over surgery in unstable patients |
Pearl
The critical view of safety is the single most important step in safe laparoscopic cholecystectomy: dissect Calot triangle until only two structures (cystic duct and cystic artery) enter the gallbladder, with the lower third of the gallbladder mobilized off the liver bed. If the critical view cannot be obtained safely, perform subtotal cholecystectomy or convert to open rather than risk common bile duct injury.
Pitfall
Do not anchor on negative ultrasound findings in patients with high pretest probability. Ultrasound sensitivity for acute cholecystitis is only 81%, and obesity, bowel gas, and operator experience all reduce yield. Proceed to CT or HIDA when ultrasound is equivocal but clinical suspicion remains high; missed cholecystitis progresses to gangrene within 24-48 hours.
Pearl
In Grade III cholecystitis, the ICU resuscitation phase is not a delay before drainage; it is the drainage. Lactate clearance, vasopressor weaning, and source control via PT-GBD performed in the first 6-12 hours are independently associated with lower 30-day mortality in biliary sepsis. Antibiotics alone without source control fail in nearly all Grade III patients.
Pitfall
Do not assume that cystic duct stones excluded by ERCP equate to cleared common bile duct. Up to 15% of patients with acute cholecystitis have concomitant choledocholithiasis. Check liver enzymes, perform MRCP if elevated bilirubin or dilated CBD on US, and proceed with intraoperative cholangiography or ERCP based on probability stratification (ASGE 2019 high-risk criteria: bilirubin >4, dilated CBD >6 mm with elevated bilirubin, visible CBD stone on US).
Frequently Asked Questions
- Acute Cholecystitis: Tokyo Guidelines 2018 Diagnosis, Antibiotic Therapy, and Early Cholecystectomy
- Ischemic Colitis: ACG Diagnosis with CT, Colonoscopy Severity Grading, and Conservative versus Surgical Management
- Alcoholic Hepatitis: Diagnosis, Severity Assessment, and Treatment
- Acute Mesenteric Ischemia: Diagnosis and Management
- Acute Pancreatitis — Diagnosis and Evidence-Based Management
- Acute Appendicitis: WSES and EAES Diagnosis with Alvarado AIR Score CT Imaging and Laparoscopic Appendectomy
Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.
- Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (Journal of Hepato-Biliary-Pancreatic Sciences · 2018)